DAWN vs. ANIP, MNKD, BLTE, MIRM, KNSA, GMTX, PRTA, PCRX, ABCL, and SYRE
Should you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include ANI Pharmaceuticals (ANIP), MannKind (MNKD), Belite Bio (BLTE), Mirum Pharmaceuticals (MIRM), Kiniksa Pharmaceuticals (KNSA), Gemini Therapeutics (GMTX), Prothena (PRTA), Pacira BioSciences (PCRX), AbCellera Biologics (ABCL), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical preparations" industry.
ANI Pharmaceuticals (NASDAQ:ANIP) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.
ANI Pharmaceuticals has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.44, indicating that its share price is 244% less volatile than the S&P 500.
ANI Pharmaceuticals has a net margin of 6.87% compared to ANI Pharmaceuticals' net margin of 0.00%. Day One Biopharmaceuticals' return on equity of 17.15% beat ANI Pharmaceuticals' return on equity.
ANI Pharmaceuticals currently has a consensus target price of $81.00, suggesting a potential upside of 30.84%. Day One Biopharmaceuticals has a consensus target price of $37.67, suggesting a potential upside of 178.60%. Given ANI Pharmaceuticals' higher possible upside, analysts clearly believe Day One Biopharmaceuticals is more favorable than ANI Pharmaceuticals.
ANI Pharmaceuticals has higher revenue and earnings than Day One Biopharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 8.4% of Day One Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, ANI Pharmaceuticals had 5 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 9 mentions for ANI Pharmaceuticals and 4 mentions for Day One Biopharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.97 beat Day One Biopharmaceuticals' score of 0.93 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media.
ANI Pharmaceuticals received 394 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. Likewise, 64.64% of users gave ANI Pharmaceuticals an outperform vote while only 58.18% of users gave Day One Biopharmaceuticals an outperform vote.
Summary
ANI Pharmaceuticals beats Day One Biopharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get Day One Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Day One Biopharmaceuticals Competitors List
Related Companies and Tools
